WINT

U.S. Stock Market Midday Update

Windtree Therapeutics fell 10.61%, with increased trading volume. Based on recent important news:

1. On July 29, investors chose to redeem or convert most of the Series C and D preferred shares, leading to a 10.61% drop in stock price.

2. On July 30, Hang Lung Group released its interim performance report, with shareholders' profit down 21.51% year-on-year, affecting market sentiment.

3. On July 31, Asia Financial announced that it confirmed unusual fluctuations in stock price and trading volume, with no abnormal reasons found.

Stocks with High Trading Volume in the Industry

AbbVie rose 2.12%, with increased trading volume. Based on recent important news:

1. On July 31, AbbVie announced second-quarter results that exceeded expectations, with revenue of $15.42 billion, a year-on-year increase of 6.6%, driving the stock price up 2.12%.

2. On July 31, AbbVie raised its full-year profit forecast, expecting adjusted EPS to be between $11.88 and $12.08, with a positive market reaction.

3. On July 31, AbbVie is in talks to acquire Gilgamesh Pharmaceuticals for approximately $1 billion, boosting market confidence.

Regeneron Pharmaceuticals rose 0.64%, with increased trading volume. Based on recent important news:

1. On August 1, Regeneron Pharmaceuticals announced second-quarter financial results, with revenue reaching $3.68 billion, exceeding expectations, driving the stock price up 0.64%.

2. On August 1, Eylea's U.S. sales fell by 25%, but Sanofi's antibody profits grew to $1.28 billion, with a positive market reaction.

3. On August 1, the U.S. FDA rejected Regeneron's blood cancer treatment plan, with limited impact.

Alnylam Pharmaceuticals rose 1.08%, with a trading volume of $160 million. Based on recent important news:

1. On July 31, Alnylam Pharmaceuticals raised its full-year revenue forecast for 2025, with the stock price rising by 16%. The company increased its total net product revenue forecast for 2025 from $2.05 billion to $2.25 billion to $2.65 billion to $2.8 billion.

2. On August 1, Alnylam Pharmaceuticals reported a 17% year-on-year increase in second-quarter sales, reaching $773.69 million, exceeding market expectations.

3. On August 1, Needham raised Alnylam Pharmaceuticals' target stock price from $377 to $478.

Stocks with High Market Capitalization in the Industry

Amgen fell 0.44%, with increased trading volume. Based on recent key news:

1. On July 31, market analysts pointed out that Amgen was not included in the list of five stocks recommended by top analysts, leading to a decline in investor confidence and a drop in stock price

2. On July 29th, market analysts maintained Amgen's rating at Hold, without giving a Buy recommendation, further dampening market sentiment.

3. On July 30th, the overall market expressed concerns about the long accounts receivable cycle in the healthcare industry, affecting the stock performance of several companies, including Amgen